04/08/2026
A pioneering cell-based immunotherapy designed to treat rare, aggressive blood cancers has received Breakthrough Therapy designation from the FDA.
Developed by researchers at WashU Medicine and licensed to Wugen—a WashU Medicine startup based in the Cortex Innovation District—this innovative CAR-T cell therapy represents a promising advancement in the fight against hard-to-treat cancers.
Learn more about this therapy > https://internalmedicine.wustl.edu/innovative-car-t-cell-therapy-receives-fda-breakthrough-therapy-designation/